See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Microsoft Corporation (MSFT) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Microsoft Corporation (MSFT) - free report >>
Volatility Is Here To Stay
The past 8 trading days have experienced 1,000+ point Dow swings, and the VIX (the fear index) closed at 82.69 on Monday (March 16th), its highest level in history. The length and extent of this pandemic effects are still highly ambiguous.
The markets have priced in a recession with the S&P 500 roughly 30% off its highs. Analysts are anticipating significant GDP declines for at least the first two quarters of 2020 and could extend into Q3.
One thing is clear: the market volatility will remain until this virus is under control. Fund managers and analysts are now anticipating a U-shaped recovery, a change from the rapid V-shaped recovery that was initially expected.
As a long-term investor, I am beginning to buy discounted equities with caution. Price-averaging down on all the red days. I am slowly adding positions in stocks like Adobe (ADBE - Free Report) , Facebook , Microsoft (MSFT - Free Report) , and Disney (DIS - Free Report) .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>